Core Insights - The company achieved total revenue of 574 million RMB in 2025, driven by strong commercialization growth [1] - The first commercial product, Nairike (Aorebatin), saw significant sales growth of 435 million RMB, an increase of 81% year-on-year [1] - The second product, Lishengtuo (Lisatrakra), generated sales of 70.58 million RMB within five months of its approval in July 2025 [1] - The company reported a total cash position of approximately 2.47 billion RMB, indicating improved cash flow [1] Global Clinical Development - The company achieved milestone breakthroughs with global Phase III studies for Nairike in treating Ph+ ALL and Lishengtuo for high-risk MDS, both receiving approvals from the FDA and EMA in 2025 [1] - Multiple Phase III clinical studies are currently underway globally, with four studies having received FDA and EMA approvals [1] Commercialization and Team Expansion - The commercialization team expanded rapidly, exceeding 270 personnel by the end of 2025, covering over 1,500 hospitals nationwide [2] - The company successfully listed on NASDAQ in January 2025, becoming the first biopharmaceutical company to have a dual primary listing in Hong Kong and the U.S. [2] Strategic Vision - The CEO emphasized that 2025 was a pivotal year for the company's global expansion, achieving breakthroughs in commercialization, clinical development, pipeline innovation, and capital markets [2] - The company aims to focus on unmet patient needs and accelerate global clinical development of core products, aspiring to become a global leader in the field of hematologic oncology innovation [2]
亚盛医药-B(06855)双引擎驱动高增长，耐立克销售同比大增81%